Lipocine Inc. Files 8-K Report

Ticker: LPCN · Form: 8-K · Filed: 2025-01-13T00:00:00.000Z

Sentiment: neutral

Topics: sec-filing, 8-k, regulatory

TL;DR

Lipocine filed a routine 8-K, no major news.

AI Summary

Lipocine Inc. filed an 8-K on January 13, 2025, reporting other events and financial statements. The filing does not contain specific financial figures or material events beyond the standard reporting requirements.

Why It Matters

This filing indicates Lipocine Inc. is meeting its regulatory reporting obligations with the SEC, which is standard for publicly traded companies.

Risk Assessment

Risk Level: low — The filing is a standard SEC report and does not disclose any new material risks or events.

Key Players & Entities

FAQ

What is the primary purpose of this 8-K filing for Lipocine Inc.?

The primary purpose of this 8-K filing is to report 'Other Events' and 'Financial Statements and Exhibits' as of January 13, 2025.

What is the exact date of the earliest event reported in this filing?

The date of the earliest event reported is January 13, 2025.

What is Lipocine Inc.'s principal executive office address?

Lipocine Inc.'s principal executive office is located at 675 Arapeen Drive, Suite 202, Salt Lake City, Utah 84108.

What is Lipocine Inc.'s Commission File Number?

Lipocine Inc.'s Commission File Number is 001-36357.

Does this filing indicate any significant changes or material events for Lipocine Inc.?

Based on the provided text, this filing appears to be a routine report of 'Other Events' and 'Financial Statements and Exhibits' without specifying any significant new material events.

From the Filing

0001493152-25-001841.txt : 20250113 0001493152-25-001841.hdr.sgml : 20250113 20250113060447 ACCESSION NUMBER: 0001493152-25-001841 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 61 CONFORMED PERIOD OF REPORT: 20250113 ITEM INFORMATION: Other Events ITEM INFORMATION: Financial Statements and Exhibits FILED AS OF DATE: 20250113 DATE AS OF CHANGE: 20250113 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Lipocine Inc. CENTRAL INDEX KEY: 0001535955 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] ORGANIZATION NAME: 03 Life Sciences IRS NUMBER: 990370688 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-36357 FILM NUMBER: 25524631 BUSINESS ADDRESS: STREET 1: 675 ARAPEEN DRIVE, SUITE 202 CITY: SALT LAKE CITY STATE: X1 ZIP: 84108 BUSINESS PHONE: 801 994 7383 MAIL ADDRESS: STREET 1: 675 ARAPEEN DRIVE, SUITE 202 CITY: SALT LAKE CITY STATE: X1 ZIP: 84108 FORMER COMPANY: FORMER CONFORMED NAME: MARATHON BAR CORP DATE OF NAME CHANGE: 20111130 8-K 1 form8-k.htm false 0001535955 0001535955 2025-01-13 2025-01-13 iso4217:USD xbrli:shares iso4217:USD xbrli:shares       UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549   FORM 8-K   CURRENT REPORT   Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934   Date of Report (Date of Earliest Event Reported): January 13, 2025     LIPOCINE INC. (Exact name of registrant as specified in its charter)   Commission File No. 001-36357   Delaware   99-0370688 (State or other jurisdiction of incorporation)   (IRS Employer Identification Number)   675 Arapeen Drive , Suite 202 Salt Lake City , Utah 84108 (Address of principal executive offices) (Zip Code)   Registrant’s telephone number, including area code: (801) 994-7383   Former name or former address, if changed since last report: Not Applicable       Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:   ☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)     ☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)     ☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))     ☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))   I Securities registered pursuant to Section 12(b) of the Act:   Title of each class   Trading Symbol(s)   Name of each exchange on which registered Common Stock, par value $0.0001 per share   LPCN   The NASDAQ Stock Market LLC   Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (17 CFR § 230.405) or Rule 12b-2 of the Securities Exchange Act of 1934 (17 CFR § 240.12b-2).   Emerging growth company ☐   If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐             Item 8.01 Other Events   The Company has updated its corporate presentation that it uses when meeting with investors, analysts and others. The presentation is filed as Exhibit 99.1.   Item 9.01 Financial Statements and Exhibits.   (d) Exhibits   The following exhibits are filed with this report:   Exhibit No.   Description 99.1   Corporate Presentation 104   Cover Page Interactive Data File (embedded within the Inline XBRL document)         SIGNATURES   Pursuant to the

View on Read The Filing